Unituxin
(Dinutuximab)Phase 3Monoclonal antibody
United TherapeuticsDinutuximab is used to treat a type of childhood cancer called neuroblastoma. It works by helping the immune system recognize and destroy cancer cells.[1] Unituxin is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Unituxin is one of 63 biologic programs targeting Recurrent Ganglioneuroblastoma. It is currently in Phase 3.
4
Indications
20
Total Trials
11
Active Trials
62
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Vepesid
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Leukine
SanofiPhase 3
Camptosar
PfizerPhase 3
Tepadina
Jazz PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroblastoma10 trials
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02573896·13 enrolled
Show 7 more trials
High-Risk Neuroblastoma2 trials
Small Cell Lung Cancer1 trial
Osteosarcoma1 trial
5 more indications
Relapsed Neuroblastoma1 trial
Recurrent Neuroblastoma1 trial
Ganglioneuroblastoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Mar 10, 2015
UNITUXIN
BLA BLA125516
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dinutuximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company